Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis

DOI Web Site

Bibliographic Information

Other Title
  • 当科における関節リウマチに対するトシリズマブの治療効果の検討
  • 当科[三重大学大学院医学系研究科整形外科]における関節リウマチに対するトシリズマブの治療効果の検討
  • トウ カ ミエ ダイガク ダイガクイン イガクケイ ケンキュウカ セイケイ ゲカ ニ オケル カンセツ リウマチ ニ タイスル トシリズマブ ノ チリョウ コウカ ノ ケントウ

Search this article

Abstract

Objective: The objective of this retrospective study was to determine the responses to tocilizumab among 34 patients with rheumatoid arthritis (RA).<br>Methods: Information from 34 patients with RA who were treated with tocilizumab was analyzed. Disease activity was assessed using disease activity score 28 (DAS28). Treatment responses at week 12 and 24 were assessed using the response criteria of the European League Against Rheumatism (EULAR).<br>Results: Thirty-three (97.1%) patients completed 24 weeks of tocilizumab treatment. The mean DAS28-ESR values at weeks 12 and 24 decreased significantly compared to baseline values. The mean (±SD) DAS28-ESR value decreased significantly from 4.90 (±1.65) at baseline to 2.19 (±1.10) at week 24. At week 24, using the EULAR response criteria, good, moderate, and no responses were 63.6%, 30.3%, and 6.1%, respectively. A good or moderate response was achieved in 93.9% of patients. The overall incidence of adverse events (AEs) was 70.6% (serious AEs: 11.7%). All serious AEs improved with adequate treatment.<br>Conclusions: Tocilizumab was safe, tolerable, and clinically effective after 24 weeks for patients with RA.

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top